TNFRSF17 and Miyoshi myopathy: The outstanding efficacy and low adverse toxicity of cilta-cel observed in Legend-2 and CARTITUDE-1 studies propelled it further to receive FDA approval on 28 February 2022 as the second approved anti-BCMA-CAR T-cell product in treating triple class exposed MM (28).